aetna™

2020 Procrit® (epoetin alfa) Prior Authorization Request

Page 1 of 3

(You must complete all pages.)

Fax completed form to: 1-800-408-2386 **For urgent requests, please call: 1-800-414-2386**

Coverage Criteria:

- Medication is covered on plan if determined not to be covered under Medicare Part A or Medicare Part B AND when being prescribed for anemia due to chronic kidney disease in patients not on dialysis, anemia due to myelosuppressive anticancer chemotherapy in patients with non-myeloid malignancies in which chemotherapy is not being given with a curative intent, anemia due to zidovudine therapy in an HIV-infected patient, reduction of allogenic red blood cell transfusion in patients undergoing elective, noncardiac, nonvalvular surgery, anemia due to myelodysplastic syndromes, anemia in congestive heart failure, anemia due to rheumatoid arthritis, anemia due to hepatitis C treatment (ribavirin in combination with either interferon alfa or peginterferon alfa), anemia due to primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, anemia in patients whose religious beliefs forbid blood transfusions and anemia in cancer patients who are undergoing palliative treatment

- **For ALL REQUESTS (except surgery)**: patients must have a PRE-TREATMENT (no erythropoietin treatment in previous month) hemoglobin (Hgb) of less than 10 g/dL (or less than 9 g/dL for anemia in CHF only).

- **For patients with primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia:**
  - Patient must have symptomatic anemia
    AND
  - For **INITIAL therapy,** PRE-TREATMENT (no erythropoietin treatment in previous month) serum erythropoietin levels must be less than 500 mU/ml
- **For patients undergoing surgery:**
  - Procedure must be elective, noncardiac, nonvascular surgery
    AND
  - PRE-TREATMENT hemoglobin (Hgb) level is greater than 10 g/dL but not more than 13 g/dL
- **For CONTINUATION OF THERAPY for ALL patients, except surgery:**
  - There must be an increase in hemoglobin (Hgb) of at least 1 g/dL after at least 12 weeks of therapy in patients not recently transfused
    AND
  - **For anemia due to myelosuppressive cancer chemotherapy:** Current hemoglobin (Hgb) must be less than 11 g/dL
  - **For all other uses, except surgery and for anemia due to chemotherapy:** Current hemoglobin (Hgb) must be less than or equal to 12 g/dL

Authorization duration: 16 weeks

Patient information		**Prescriber information**	
Patient name		Today's date	Physician specialty
Patient insurance ID number		Physician name	NPI/DEA number
Patient address, city, state, ZIP		Physician address, city, state, ZIP	
Patient home telephone number		M.D. office telephone number	
Gender ☐ Male ☐ Female	Patient date of birth	M.D. office fax number	
Diagnosis and medical information			
Medication requested ☐ Procrit			

(continued on page 2)

Diagnosis and medical information (continued):

Diagnosis

- ☐ Anemia due to chronic kidney disease (CKD)
- ☐ Anemia due to end stage renal disease (ESRD) with DIALYSIS
- ☐ Anemia due to myelosuppressive anticancer chemotherapy in patients with non-myeloid malignancies
- ☐ Anemia due to zidovudine therapy in an HIV-infected patient with endogenous serum erythropoietin levels less than or equal to 500 mU/mL.
- ☐ Elective, noncardiac, nonvascular surgery; to reduce the need for allogeneic red blood cell transfusions among patients with perioperative hemoglobin between 10-13 g/dL who are at high risk for perioperative blood loss
- ☐ Anemia due to myelodysplastic syndromes (MDS)
- ☐ Anemia in congestive heart failure (CHF)
- ☐ Anemia in rheumatoid arthritis (RA)
- ☐ Anemia due to hepatitis C treatment (ribavirin in combination with either interferon alfa or peginterferon alfa)
- ☐ Anemia in primary myelofibrosis
- ☐ Anemia in post-polycythemia vera myelofibrosis
- ☐ Anemia in post-essential thrombocythemia myelofibrosis
- ☐ Anemia in patients whose religious beliefs forbid blood transfusions
- ☐ Cancer patients who are undergoing palliative treatment
- ☐ Other diagnosis/(ICD10): _____

Strength and route of administration	Quantity	Day supply	Expected length of therapy

Please check all boxes that apply:

☐ New start ☐ Restart ☐ Renewal

1. Where is medication being administered?

- ☐ Patient's home (self-administered)
- ☐ Ambulatory infusion center (infusion center supplies drug)
- ☐ Ambulatory infusion center (pharmacy supplies drug)
- ☐ Office administered (office supplies drug) / J CODE: _____
- ☐ Office administered (pharmacy supplies drug)
- ☐ Dialysis Center administered (dialysis center supplies drug)
- ☐ Other: _____

2. ☐ Yes ☐ No **Is the patient currently on dialysis or will the patient be starting dialysis soon? If yes, please answer the following:**

☐ Yes ☐ No Is the Procrit to be used for a dialysis-related condition?

3. ☐ **Patient is stable on current drug(s) and/or current quantity, and therapy change would likely result in adverse clinical outcome**

4. ☐ **All covered Part D drugs on any tier of the plan's formulary would not be as effective for the enrollee as the requested formulary drug and/or would likely have adverse effects for the enrollee.**

5. ☐ Yes ☐ No **For all uses EXCEPT surgical procedures, was the patient's PRE-TREATMENT (no erythropoietin treatment in previous month) hemoglobin (Hgb) level less than 10 g/dL (or less than 9 g/dL for anemia in CHF only)?**

Hgb level: _____ g/dL; Date: _____

6. For elective, noncardiac, nonvascular surgery use:

☐ Yes ☐ No **Does the patient have a PRE-TREATMENT hemoglobin (Hgb) level greater than 10 g/dL but not more than 13 g/dL?**

Hgb level: _____ g/dL; Date: _____

7. For a diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis:

☐ Yes ☐ No **Does the patient have symptomatic anemia?**

☐ Yes ☐ No **Is/was the PRE-TREATMENT serum erythropoietin level LESS than 500 mU/mL?**

EPO level: _____ mU/mL; Date: _____

(continued on page 3)

Please check all boxes that apply *(continued)*:

8. ☐ Yes ☐ No **Is the patient receiving chemotherapy with curative intent?**

☐ Yes ☐ No **Does the patient have myeloid cancer (such as acute myeloid leukemia [AML] or chronic myeloid leukemia [CML])?**

9. For RENEWALS, please provide most current hemoglobin (Hgb) level: _____g/dL and complete this section.

☐ Yes ☐ No **Has the patient had a recent blood transfusion?**

☐ Yes ☐ No **If no recent blood transfusion, has there been an increase in hemoglobin (Hgb) of at least 1 g/dL after at least 12 weeks of therapy?**

☐ Yes ☐ No **For anemia due to myelosuppressive anticancer chemotherapy, does the patient have a current hemoglobin (Hgb) of less than 11 g/dL?**

☐ Yes ☐ No **For all other diagnoses except surgical procedures, does the patient have a current hemoglobin (Hgb) less than or equal to 12 g/dL?**

10. ☐ **Other supporting information:**

*NOTE: Requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.

_____

_____

_____

_____

_____

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.

Prescriber signature	**Date**